Can Zaynich do for Wockhardt what Ozempic did for Novo Nordisk?

July 6, 2024

Wockhardt’s Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk’s Ozempic, Zaynich’s $25 billion potential counters global antibiotic resistance.

More To Explore

Tariff shock turns FIIs to sellers in April. Analysts flag global risk but back India’s fundamentals

Foreign institutional investors reversed course in early April, spurred by rising global trade tensions following US President Trump’s announcement of steep tariffs. This led to

April 5, 2025

F&O Talk| Trade turmoil triggers technical breakdown: Nifty sheds 1,000 pts in 8 sessions. Sudeep Shah weighs in

Benchmark indices Sensex and Nifty 50 fell by 2.6% each due to a global sell-off triggered by U.S. tariff actions. IT stocks suffered the most,

April 5, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003